Claims for Patent: 6,133,324

Summary for Patent: 6,133,324

Title:	Use of perillyl alcohol in organ transplantation
Abstract:	Perillyl alcohol and its monoterpene derivatives used alone or in combination with existing immunosuppressive agents, such as cyclosporine A and azathioprine, to provide methods and compositions which reduce allograft rejection in organ transplant patients.
Inventor(s):	Imagawa; David K. (Orange, CA), Ming-Sing; Si (Santa Ana, CA)
Assignee:	The Regents of The University of California (Oakland, CA)
Application Number:	09/305,997
Patent Claims:	1. A method for treating a transplant patient wherein said patient receives a donor organ and wherein there is a possibility of allograft rejection of said organ, said method comprising the step of administering to said patient an immunosuppressive effective amount of perillyl alcohol or a derivative thereof, said step of administering said perillyl alcohol or derivative thereof being carried out for a sufficient time to create tolerance in said patient to said allograft rejection of said organ. 2. A method for treating a transplant patient according to claim 1 wherein said perillyl alcohol or a derivative thereof is administered to said patient both before and after said patient receives said donor organ. 3. A method for treating a transplant patient according to claim 1 wherein said perillyl alcohol or a derivative thereof is administered to said patient orally. 4. A method for treating a transplant patient according to claim 1 wherein an immunosuppressive agent is also administered to said transplant patient, said immunosuppressive agent being selected from the group consisting of cyclosporine A, tacrilomus, corticosteriods, mycophenolate mofetil, mizoribine, brequinar sodium, 15-deoxyspergualin, rapamycin, azathioprine cyclophosphamide, antilymphocyte antibodies, antithymocyte antibodies and muromonab-CD3. 5. A method for treating a transplant patient according to claim 4 wherein said immunosuppressive agent is cyclosporine A. 6. In a method for treating an organ transplant patient wherein a given dosage of immunosuppressive agent is administered to said patient to reduce the possibility of allograft rejection, the improvement comprising the step of reducing the amount of said given dosage of said immunosuppressive agent and administering to said patient an immunosuppressive effective amount of perillyl alcohol or a derivative thereof, said step of administering said perillyl alcohol or derivative thereof being carried out for a sufficient time to create tolerance in said patient to said allograft rejection of said organ. 7. An improved method according to claim 6 wherein said immunosuppressive agent is selected from the group consisting of cyclosporine A, tacrilomus, corticosteriods, mycophenolate mofetil, mizoribine, brequinar sodium, 15-deoxyspergualin, rapamycin, azathioprine cyclophos-phamide, antilymphocyte antibodies, antithymocyte antibodies and muromonab-CD3. 8. An improved method according to claim 7 wherein said immunosuppressive agent is cyclosporine A. 9. An improved method according to claim 5 wherein said perillyl alcohol or a derivative thereof is administered to said patient orally. 10. An improved method according to claim 5 wherein said perillyl alcohol or a derivative thereof is administered to said patient both before and after transplantation of said organ.

Details for Patent 6,133,324

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Centocor Ortho Biotech Products, L.p.	ORTHOCLONE OKT3	muromanab-cd3	Injection	103463	September 14, 1992	6,133,324	2019-05-06